(36B5) MSCI EM SRI USD - Overview
Etf: Stocks, Emerging Markets, Sustainability, Technology, Financial
Dividends
| Dividend Yield | 2.61% |
| Yield on Cost 5y | 2.26% |
| Yield CAGR 5y | 3.86% |
| Payout Consistency | 94.8% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 14.2% |
| Relative Tail Risk | -3.08% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.95 |
| Alpha | 14.98 |
| Character TTM | |
|---|---|
| Beta | 0.215 |
| Beta Downside | 0.430 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.57% |
| CAGR/Max DD | 0.52 |
Description: 36B5 MSCI EM SRI USD December 18, 2025
The iShares MSCI EM SRI UCITS ETF (USD Dist) ( ticker 36B5 ) is a Germany-domiciled exchange-traded fund that tracks the Morningstar Emerging Markets Total Market Ex-Net-Return USD index, offering investors exposure to a broad basket of equity securities across developing economies.
Key characteristics (as of the most recent public data) include an expense ratio of roughly 0.25 % and assets under management estimated at €2-3 billion, making it a relatively liquid vehicle in the global emerging-markets space. The fund’s top holdings are typically large-cap firms in China, Taiwan and South Korea, with sector weightings skewed toward financials (≈30 %) and technology (≈20 %). Its “SRI” mandate screens for ESG criteria, which can affect sector composition by underweighting high-carbon industries such as oil & gas.
From a macro perspective, the ETF’s performance is closely tied to emerging-market GDP growth (average 5-6 % y/y in 2023) and commodity price cycles, while the ongoing slowdown in China and tightening of global monetary policy introduce downside risk. Investors should monitor real-effective exchange-rate movements and sovereign credit spreads, as these can materially impact net returns.
For a deeper quantitative dive, you might explore ValueRay’s analytics platform to benchmark this ETF against peers and stress-test its exposure to the drivers above.
What is the price of 36B5 shares?
Over the past week, the price has changed by +1.61%, over one month by +3.06%, over three months by +9.68% and over the past year by +22.42%.
Is 36B5 a buy, sell or hold?
What are the forecasts/targets for the 36B5 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 7.4 | 25.1% |
36B5 Fundamental Data Overview February 03, 2026
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 503.9m EUR (503.9m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 503.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 503.9m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.71% (E(503.9m)/V(503.9m) * Re(6.71%) + (debt-free company))
Discount Rate = 6.71% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)